Medpace (NASDAQ: MEDP) — Company Overview, News & Financial Data
Medpace is a full-service CRO supporting clinical trials for pharmaceutical and biotechnology industries, ensuring efficient therapy development.
Medpace
Medpace is a global contract research organization providing Phase I through Phase IV clinical development services to the biotechnology, pharmaceutical, and medical device industries. Headquartered in Cincinnati, Ohio, the company offers integrated services including clinical trial management, study start-up, clinical monitoring, biostatistics, data management, medical writing, and regulatory affairs. Additionally, it operates central laboratories, bioanalytical laboratories, core imaging facilities, and cardiovascular safety labs to support drug and device development. The organization specializes in complex therapeutic areas such as oncology, cardiology, metabolic diseases, infectious diseases, and neuroscience, partnering with biopharmaceutical sponsors to execute multi-center global clinical trials.
Snapshot
Operations
Products and/or services of Medpace
- Clinical Trial Management: Comprehensive execution of early to late-phase global clinical studies, encompassing site selection, patient recruitment, clinical monitoring, biostatistics, data management, medical writing, and regulatory filings across primary therapeutic areas including oncology, cardiology, and metabolic disorders.
- Central Laboratory Services: Integrated safety testing, biomarker development, microbiology capabilities, and biorepository storage conducted through purpose-built laboratory facilities supporting multi-center international trial programs with standardized analytical procedures, automated data workflows, and centralized logistics.
- Bioanalytical Laboratory Services: Specialized discovery and development testing services, including pharmacokinetic and toxicokinetic evaluation, immunogenicity assays, biomarker measurement, and anti-drug antibody profiling to support preclinical compounds and human clinical study analysis.
- Core Imaging Services: Comprehensive medical imaging operational support and quantitative image analysis covering nuclear medicine, oncology, musculoskeletal, central nervous system, and cardiovascular endpoints utilizing standardized imaging protocols across participating clinical investigative sites.
- Electrocardiography and Cardiac Safety: Centralized electrocardiogram monitoring, continuous telemetry data acquisition, and wearable biosensor integration providing cardiac risk evaluation, safety data analysis, and expert medical interpretation throughout all phases of biopharmaceutical clinical development.
- Phase I Clinical Research Units: Specialized clinical facilities dedicated to executing complex early-phase clinical trials, conducting first-in-human studies, bioavailability assessments, pharmacokinetic evaluations, and intensive pharmacodynamic protocol execution for biopharmaceutical sponsors.
Medpace executive team
- Dr. August James Troendle M.D.Chairman & CEO
- Mr. Jesse J. Geiger BBA, CPAPresident
- Mr. Kevin M. BradyCFO & Treasurer
- Ms. Susan E. Burwig BSN, MAExecutive Vice President of Operations
- Mr. Stephen P. Ewald J.D.Chief Compliance Officer, General Counsel & Corporate Secretary
- Mr. Brandon EbkenChief Information Officer
- Ms. Lauren MorrisAssociate Director of Investors Relations
- Mr. Todd MeyersVice President of Business Development & Marketing
- Mr. Weimin Gai MSSenior Vice President of Biometrics
- Mr. John T. Wynne MBASenior Vice President of Commercial Operations & Clinical Pharmacology Unit